Literature DB >> 19448844

Treatment of comorbid tobacco use in people with serious mental illness.

Katrina Lising-Enriquez1, Tony P George.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19448844      PMCID： PMC2674967     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  7 in total

Review 1.  Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Authors:  David Kalman; Sandra Baker Morissette; Tony P George
Journal:  Am J Addict       Date:  2005 Mar-Apr

2.  Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia.

Authors:  T P George; D M Ziedonis; A Feingold; W T Pepper; C A Satterburg; J Winkel; B J Rounsaville; T R Kosten
Journal:  Am J Psychiatry       Date:  2000-11       Impact factor: 18.112

3.  Inhibition of CYP2D6 activity by bupropion.

Authors:  Michael Kotlyar; Lisa H Brauer; Timothy S Tracy; Dorothy K Hatsukami; Jennifer Harris; Carrie A Bronars; David E Adson
Journal:  J Clin Psychopharmacol       Date:  2005-06       Impact factor: 3.153

4.  A comparison of sustained-release bupropion and placebo for smoking cessation.

Authors:  R D Hurt; D P Sachs; E D Glover; K P Offord; J A Johnston; L C Dale; M A Khayrallah; D R Schroeder; P N Glover; C R Sullivan; I T Croghan; P M Sullivan
Journal:  N Engl J Med       Date:  1997-10-23       Impact factor: 91.245

5.  Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.

Authors:  John A Stapleton; Lucy Watson; Lucy I Spirling; Robert Smith; Andrea Milbrandt; Marina Ratcliffe; Gay Sutherland
Journal:  Addiction       Date:  2007-11-19       Impact factor: 6.526

6.  A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia.

Authors:  Tony P George; Jennifer C Vessicchio; Kristi A Sacco; Andrea H Weinberger; Melissa M Dudas; Taryn M Allen; Cerissa L Creeden; Marc N Potenza; Alan Feingold; Peter I Jatlow
Journal:  Biol Psychiatry       Date:  2007-12-21       Impact factor: 13.382

7.  A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.

Authors:  A Eden Evins; Corinne Cather; Melissa A Culhane; Alan Birnbaum; Jonathan Horowitz; Elaine Hsieh; Oliver Freudenreich; David C Henderson; David A Schoenfeld; Nancy A Rigotti; Donald C Goff
Journal:  J Clin Psychopharmacol       Date:  2007-08       Impact factor: 3.153
  7 in total
  8 in total

Review 1.  New medications for drug addiction hiding in glutamatergic neuroplasticity.

Authors:  P W Kalivas; N D Volkow
Journal:  Mol Psychiatry       Date:  2011-04-26       Impact factor: 15.992

2.  Rationale, design and pilot feasibility results of a smartphone-assisted, mindfulness-based intervention for smokers with mood disorders: Project mSMART MIND.

Authors:  Haruka Minami; Hannah R Brinkman; Shadi Nahvi; Julia H Arnsten; Monica Rivera-Mindt; David W Wetter; Erika Litvin Bloom; Lawrence H Price; Carlos Vieira; Remington Donnelly; Lauren M McClain; Katherine A Kennedy; Erica D'Aquila; Micki Fine; Danielle E McCarthy; J Graham Thomas; Jacki Hecht; Richard A Brown
Journal:  Contemp Clin Trials       Date:  2017-12-27       Impact factor: 2.226

Review 3.  Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.

Authors:  Henri-Jean Aubin; Amandine Luquiens; Ivan Berlin
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 4.  Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis.

Authors:  Taro Kishi; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-10-05       Impact factor: 5.270

5.  Clinical characteristics of heavy and non-heavy smokers with schizophrenia.

Authors:  Heidi J Wehring; Fang Liu; Robert P McMahon; Kristen M Mackowick; Raymond C Love; Lisa Dixon; Deanna L Kelly
Journal:  Schizophr Res       Date:  2012-05-10       Impact factor: 4.939

Review 6.  Epigenetic approaches to psychiatric disorders.

Authors:  Carolyn Ptak; Arturas Petronis
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

7.  Association between smoking, and hospital readmission among inpatients with psychiatric illness at an academic inpatient psychiatric facility, 2000-2015.

Authors:  Robert Kagabo; Jaewhan Kim; Jon-Kar Zubieta; Kristi Kleinschmit; Kolawole Okuyemi
Journal:  Addict Behav Rep       Date:  2019-04-09

8.  Effectiveness of a multi-component Smoking Cessation Support Programme (McSCSP) for patients with severe mental disorders: study design.

Authors:  Maria Paz Garcia-Portilla; Leticia Garcia-Alvarez; Pilar Alejandra Saiz; Eva Diaz-Mesa; Gonzalo Galvan; Fernando Sarramea; Josefa Garcia-Blanco; Edorta Elizagarate; Julio Bobes
Journal:  Int J Environ Res Public Health       Date:  2013-12-24       Impact factor: 3.390
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.